Scarica l'app Stockscreener
104.79
2.60%
2.67
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BNTX Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$102.12
Aprire:
$103.52
Volume 24 ore:
278.54K
Relative Volume:
0.25
Capitalizzazione di mercato:
$26.48B
Reddito:
$3.32B
Utile/perdita netta:
$-1.26B
Rapporto P/E:
-20.03
EPS:
-5.2311
Flusso di cassa netto:
$289.80M
1 W Prestazione:
+9.72%
1M Prestazione:
+10.46%
6M Prestazione:
-0.34%
1 anno Prestazione:
+6.10%
Intervallo 1D:
$103.40
$104.98
Intervallo di 1 settimana:
$95.36
$104.98
Portata 52W:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
104.72 | 25.82B | 3.32B | -1.26B | 289.80M | -5.2311 |
VRTX
Vertex Pharmaceuticals Inc
|
439.00 | 110.81B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.53 | 78.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
843.97 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.70 | 42.71B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
326.36 | 35.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-06-05 | Reiterato | H.C. Wainwright | Buy |
| 2025-05-29 | Iniziato | Goldman | Neutral |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-01-10 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-02 | Reiterato | BMO Capital Markets | Outperform |
| 2024-11-19 | Iniziato | Berenberg | Buy |
| 2024-11-19 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-09-24 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-14 | Iniziato | Evercore ISI | In-line |
| 2024-02-23 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-05 | Iniziato | Oppenheimer | Perform |
| 2023-12-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-17 | Aggiornamento | Redburn | Neutral → Buy |
| 2022-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-08-17 | Iniziato | Cowen | Market Perform |
| 2022-07-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2021-12-16 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Iniziato | Deutsche Bank | Hold |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-08-11 | Aggiornamento | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-06-16 | Downgrade | Redburn | Neutral → Sell |
| 2021-05-18 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-08-03 | Ripresa | Berenberg | Buy |
| 2020-07-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-30 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Iniziato | H.C. Wainwright | Neutral |
| 2020-01-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Downgrade | UBS | Buy → Neutral |
| 2019-11-05 | Iniziato | Wolfe Research | Outperform |
| 2019-11-04 | Iniziato | Berenberg | Buy |
| 2019-11-04 | Iniziato | BofA/Merrill | Buy |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-11-04 | Iniziato | JP Morgan | Overweight |
| 2019-11-04 | Iniziato | SVB Leerink | Outperform |
| 2019-11-04 | Iniziato | UBS | Buy |
Mostra tutto
Biontech Se Adr Borsa (BNTX) Ultime notizie
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
BioNTech’s Malaria mRNA Vaccine Trial Reaches Completion: What Investors Should Watch - TipRanks
Lbp Am Sa Acquires 15,255 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Impfung: Between Pandemic Legacy and Oncology Pivot, Future Hinges on Pipeline Wins - AD HOC NEWS
BioNTech SE Sponsored ADR $BNTX Shares Sold by Baillie Gifford & Co. - MarketBeat
Net income of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView — Track All Markets
BioNTech SE Sponsored ADR Revenue Breakdown – BSESOF:22UA - TradingView — Track All Markets
BioNTech Earnings Call: Cash-Rich Pivot Beyond COVID - TipRanks
BNTX Stock Price, Quote & Chart | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
Operating income of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView — Track All Markets
BioNTech's Shareholder Vote to Cement Post-Pandemic Strategy () - aktiencheck.de
Why Is Pfizer Stock Dropping Tuesday? - Sahm
European ADRs Slipped As Biotech Lagged And UK Names Rose - Finimize
BioNTech Shifts Strategy with Dual Operational Pullbacks () - aktiencheck.de
BioNTech's Strategic Pivot: Fueling Oncology Ambition with Capital Reserves () - aktiencheck.de
BioNTech Shares Navigate Dual Challenges Amid Strategic Shift () - aktiencheck.de
BioNTech announces invitation to 2026 annual general meeting for May 15 - Investing.com
BioNTech's mRNA Vaccine Platform: Current Developments and Strategic Importance for North American I - AD HOC NEWS
HC Wainwright Issues Negative Estimate for BioNTech Earnings - MarketBeat
BioNTech (NASDAQ:BNTX) Given New $130.00 Price Target at HC Wainwright - Defense World
BioNTech SE (STU:22UA) Stock Price, Trades & News - GuruFocus
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know - MSN
BNTX Stock Today: March 31: ELCC Cancer Data Steady Amid Biotech Rout - Meyka
BioNTech at a Crossroads: Financial Pressures and Clinical Promise Collide () - aktiencheck.de
BioNTech's Oncology Pipeline Shows Promise with Significant Survival Data () - aktiencheck.de
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Short Interest Down 20.7% in March - MarketBeat
BioNTech SE Sponsored ADR Trade Ideas — BSESOF:22UA - TradingView
Total equity of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
ETFs Investing in BioNTech SE Sponsored ADR Stocks - TradingView
EBITDA per share of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
BioNTech’s Mpox Vaccine Study Reaches Completion: What Investors Should Watch Next - TipRanks
BioNTech SE Sponsored ADR $BNTX Shares Bought by SG Americas Securities LLC - MarketBeat
BioNTech (NASDAQ:BNTX) Receives Buy Rating from Jefferies Financial Group - defenseworld.net
BioNTech stock plunges as founders leave. Should you buy the dip in BNTX here? - MSN
BioNTech Oncology Pipeline Shows Promising Survival Data in Late-Stage Lung Cancer Trials as of Marc - AD HOC NEWS
AKT I: „ICI VARSOVIE” [c66293] - Fathom Journal
BioNTech Faces Leadership Transition Amid Pivotal Clinical Milestones () - aktiencheck.de
BioNTech's Oncology Pivot Accelerates Amid Leadership Transition and €17B Cash Reserve - AD HOC NEWS
Hudson Bay Capital Management LP Acquires 55,004 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Stock Forecast | Co-Founders Plan Departure - Capital.com
Groupama Asset Managment Trims Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech (NASDAQ:BNTX) Given “Buy” Rating at Deutsche Bank Aktiengesellschaft - Defense World
Long Focus Capital Management LLC Has $39.22 Million Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
BioNTech a Takeover Target? What's Happening at CHAR Technologies and Steyr Motors? - news.financial
symbol__ Stock Quote Price and Forecast - CNN
125,000 Shares in BioNTech SE Sponsored ADR $BNTX Purchased by Ghisallo Capital Management LLC - MarketBeat
BioNTech SE Sponsored ADR $BNTX Shares Acquired by Dodge & Cox - MarketBeat
BioNTech SE Stock (ISIN: US09075V1026) Faces Pressure After Leadership Exodus and Earnings Miss - AD HOC NEWS
BNP Paribas Financial Markets Lowers Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BNTX Stock Today: Founders to Exit; PT Cut to $167 – March 12 - Meyka
Biontech Se Adr Azioni (BNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):